IP Library Granted Patent US 8,269,009
Granted Patent B2
US 8,269,009 · App. 12/314,261 · Granted Sep 18, 2012

Methods and compositions for treating liquid tumors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,269,009
App. No.
12/314,261
Granted
Sep 18, 2012
Kind
B2
Abstract

The application relates to a method of using compositions having anti-alpha-4 integrin and/or anti-alpha-9 integrin activity to inhibit liquid tumor growth, malignancies thereof and/or development of metastases thereof that involve expression of an alpha-4 integrin and/or alpha-9 integrin. Pharmaceutical compositions and combination therapies (for example, with chemotherapies) for the inhibition of liquid tumor growth, malignancies thereof and/or development of metastases thereof are also provided.

Claims (8)

1. A method for inhibiting liquid tumor growth, malignancies thereof and/or development of metastases thereof comprising administering a therapeutically effective amount of a conjugate of formula XXII below:

wherein x, y, and z are independently an integer such that the aggregate of x, y, and z is about 100 to 1360.

2. The method of claim 1 , wherein x, y, and z are independently an integer such that the conjugate of formula XXII has a molecular weight of about 40-45 kDa.

3. The method of claim 1 , wherein the malignancy is a hematological malignancy.

4. The method of claim 3 , wherein the hematological malignancy is a leukemia or multiple myeloma.

5. The method of claim 4 , wherein the leukemia is selected from the group consisting of acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), and chronic lymphocytic leukemia (CLL).

6. A pharmaceutical composition for inhibiting liquid tumor growth, malignancies thereof and/or development of metastases thereof in a patient in need thereof, comprising a therapeutically effective amount of a conjugate of formula XXII of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, vehicle, or diluent.

7. A combination therapy for inhibiting tumor growth, malignancies and/or metastatic progression and/or development of metastases comprising administering a conjugate of formula XXII of claim 1 and a chemotherapeutic, and immunotherapeutic, and/or radiation therapy.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2013
From: ELAN PHARMA INTERNATIONAL LIMITED
To: BIOGEN IDEC INTERNATIONAL HOLDING LTD.
Reel/Frame 030204/0750 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2009
From: MESSERSMITH, ELIZABETH; LIEBERBURG, IVAN
To: ELAN PHARMACEUTICALS, INC.
Reel/Frame 022871/0098 →